NCT04521452View on ClinicalTrials.gov

Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD

PHASE4UnknownINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
CAVD
Interventions
DRUG

Evogliptin

Subjects will receive evogliptin 5 mg daily

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

REDNVIA Co., Ltd.

INDUSTRY

lead

Asan Medical Center

OTHER